ZFIN ID: ZDB-FISH-150901-17632
Fish name: rag1t26683/t26683
Genotype: rag1t26683/t26683
Targeting Reagent: none
HUMAN DISEASE MODELED by rag1t26683/t26683
No data available
GENE EXPRESSION
Gene expression in rag1t26683/t26683
RNA expression
Expressed Gene Structure Conditions Figures
acod1 standard conditions Graph Figure 1 from Novoa et al., 2019
ambp standard conditions Fig. 1 from Jima et al., 2009
bfb standard conditions Fig. 1 from Jima et al., 2009
c4b standard conditions Fig. 1 from Jima et al., 2009
c9 standard conditions Fig. 1 from Jima et al., 2009
caspa standard conditions Figure 6 with imageGraph Figure 1 from Novoa et al., 2019
chemical treatment by environment: navitoclax Figure 6 with image from Novoa et al., 2019
cat standard conditions Graph Figure 4 from Novoa et al., 2019
cbln8 standard conditions Fig. 1 from Jima et al., 2009
cd4-1 diet Fig. 5 from Coronado et al., 2019
cdkn1a standard conditions Figure 5 with image from Novoa et al., 2019
chemical treatment by environment: navitoclax Figure 5 with image from Novoa et al., 2019
cdkn1bb standard conditions Figure 5 with image from Novoa et al., 2019
chemical treatment by environment: navitoclax Figure 5 with image from Novoa et al., 2019
cdkn1ca standard conditions Figure 5 with image from Novoa et al., 2019
chemical treatment by environment: navitoclax Figure 5 with image from Novoa et al., 2019
cdkn2a/b standard conditions Figure 5 with image from Novoa et al., 2019
chemical treatment by environment: navitoclax Figure 5 with image from Novoa et al., 2019
cdkn2c standard conditions Figure 5 with image from Novoa et al., 2019
chemical treatment by environment: navitoclax Figure 5 with image from Novoa et al., 2019
csf1b standard conditions Figure 6 with image from Novoa et al., 2019
chemical treatment by environment: navitoclax Figure 6 with image from Novoa et al., 2019
cxcl8a standard conditions Fig. 2Fig. 4 from Brugman et al., 2014
cxcl8b.1 standard conditions Fig. 2 from Brugman et al., 2014
fgg standard conditions Fig. 1 from Jima et al., 2009
ifng1 chemical treatment by injection: poly(I:C) text only from Tokunaga et al., 2017
ifng1r chemical treatment by injection: poly(I:C) text only from Tokunaga et al., 2017
ifnphi1 chemical treatment by injection: poly(I:C) text only from Tokunaga et al., 2017
il1b standard conditions Figure 6 with image from Novoa et al., 2019
chemical treatment by injection: poly(I:C) Figure 6 with image from Novoa et al., 2019
text only from Tokunaga et al., 2017
il6 standard conditions Figure 6 with image from Novoa et al., 2019
il10 chemical treatment by injection: poly(I:C) text only from Tokunaga et al., 2017
il12a chemical treatment by injection: poly(I:C) text only from Tokunaga et al., 2017
il13 chemical treatment by injection: poly(I:C) text only from Tokunaga et al., 2017
il17a/f1 diet Fig. 5 from Coronado et al., 2019
il17a/f2 chemical treatment by injection: poly(I:C) text only from Tokunaga et al., 2017
il17a/f3 chemical treatment by injection: poly(I:C) text only from Tokunaga et al., 2017
diet Fig. 5 from Coronado et al., 2019
il22 standard conditions Fig. 5 from Costa et al., 2013
diet Fig. 5 from Coronado et al., 2019
lck diet Fig. 5 from Coronado et al., 2019
mdm2 standard conditions Figure 5 with image from Novoa et al., 2019
chemical treatment by environment: navitoclax Figure 5 with image from Novoa et al., 2019
mxa standard conditions Figure 6 with imageGraph Figure 1 from Novoa et al., 2019
chemical treatment by environment: navitoclax Figure 6 with image from Novoa et al., 2019
mxe standard conditions Figure 6 with imageGraph Figure 1 from Novoa et al., 2019
chemical treatment by environment: navitoclax Figure 6 with image from Novoa et al., 2019
nfe2l2a standard conditions Graph Figure 4 from Novoa et al., 2019
nkl.1 standard conditions Fig. 6 from Pereiro et al., 2015
nkl.2 standard conditions Fig. 6 from Pereiro et al., 2015
nkl.3 standard conditions Fig. 6 from Pereiro et al., 2015
nkl.4 standard conditions Fig. 6 from Pereiro et al., 2015
nlrp12l standard conditions Graph Figure 1 from Novoa et al., 2019
prf1.1 standard conditions Fig. 6 from Varela et al., 2016
prf1.2 standard conditions Graph Figure 1 from Novoa et al., 2019
Fig. 6 from Varela et al., 2016
prf1.3 standard conditions Fig. 6 from Varela et al., 2016
prf1.5 standard conditions Fig. 6 from Varela et al., 2016
prf1.6 standard conditions Fig. 6 from Varela et al., 2016
prf1.9 standard conditions Fig. 6 from Varela et al., 2016
rag1 standard conditions Fig. 3 from Mönnich et al., 2010
shisa10.2 standard conditions Figure 6 with imageGraph Figure 1 from Novoa et al., 2019
chemical treatment by environment: navitoclax Figure 6 with image from Novoa et al., 2019
si:ch211-240l19.7 standard conditions Fig. 1 from Jima et al., 2009
sod3b standard conditions Graph Figure 4 from Novoa et al., 2019
tnfa standard conditions Figure 6 with image from Novoa et al., 2019
chemical treatment by injection: poly(I:C) Figure 6 with image from Novoa et al., 2019
text only from Tokunaga et al., 2017
tnfb chemical treatment by injection: poly(I:C) text only from Tokunaga et al., 2017
tnfrsf9a standard conditions Graph Figure 1 from Novoa et al., 2019
tp53 standard conditions Figure 5 with image from Novoa et al., 2019
chemical treatment by environment: navitoclax Figure 5 with image from Novoa et al., 2019
traj3c1-3 diet Fig. 5 from Coronado et al., 2019
trim35-14 standard conditions Graph Figure 1 from Novoa et al., 2019
vtnb standard conditions Fig. 1 from Jima et al., 2009
Reporter gene expression No data available
PHENOTYPE
Phenotype in rag1t26683/t26683
Phenotype Conditions Figures
defense response to bacterium disrupted, abnormal bacterial treatment by exposure to environment: Vibrio anguillarum text only from Tokunaga et al., 2017
digestive system cdkn2a/b expression absent, abnormal chemical treatment by environment: navitoclax Figure 5 with image from Novoa et al., 2019
digestive system cdkn2c expression absent, abnormal chemical treatment by environment: navitoclax Figure 5 with image from Novoa et al., 2019
digestive system mdm2 expression amount, ameliorated chemical treatment by environment: navitoclax Figure 5 with image from Novoa et al., 2019
digestive system mdm2 expression amount, ameliorated chemical treatment by environment: O-acetylcarnitinium Figure 5 with image from Novoa et al., 2019
digestive system il1b expression amount, ameliorated chemical treatment by environment: navitoclax Figure 6 with image from Novoa et al., 2019
digestive system il1b expression amount, ameliorated chemical treatment by environment: O-acetylcarnitinium Figure 6 with image from Novoa et al., 2019
digestive system cdkn1bb expression amount, ameliorated chemical treatment by environment: navitoclax Figure 5 with image from Novoa et al., 2019
digestive system cdkn1bb expression amount, ameliorated chemical treatment by environment: O-acetylcarnitinium Figure 5 with image from Novoa et al., 2019
digestive system cdkn1a expression amount, ameliorated chemical treatment by environment: navitoclax Figure 5 with image from Novoa et al., 2019
digestive system cdkn2c expression decreased amount, abnormal chemical treatment by environment: O-acetylcarnitinium Figure 5 with image from Novoa et al., 2019
digestive system sod3b expression decreased amount, abnormal standard conditions Graph Figure 4 from Novoa et al., 2019
digestive system cat expression decreased amount, abnormal standard conditions Graph Figure 4 from Novoa et al., 2019
digestive system cdkn1ca expression decreased amount, abnormal chemical treatment by environment: navitoclax Figure 5 with image from Novoa et al., 2019
digestive system cdkn2a/b expression decreased amount, abnormal chemical treatment by environment: O-acetylcarnitinium Figure 5 with image from Novoa et al., 2019
digestive system tp53 expression decreased amount, abnormal chemical treatment by environment: O-acetylcarnitinium Figure 5 with image from Novoa et al., 2019
digestive system tp53 expression decreased amount, abnormal chemical treatment by environment: navitoclax Figure 5 with image from Novoa et al., 2019
digestive system mxe expression increased amount, abnormal standard conditions Figure 6 with image from Novoa et al., 2019
digestive system mxa expression increased amount, abnormal standard conditions Figure 6 with image from Novoa et al., 2019
digestive system cdkn1bb expression increased amount, abnormal standard conditions Figure 5 with image from Novoa et al., 2019
digestive system mxa expression increased amount, abnormal chemical treatment by environment: O-acetylcarnitinium Figure 6 with image from Novoa et al., 2019
digestive system mxa expression increased amount, abnormal chemical treatment by environment: navitoclax Figure 6 with image from Novoa et al., 2019
digestive system caspa expression increased amount, abnormal chemical treatment by environment: O-acetylcarnitinium Figure 6 with image from Novoa et al., 2019
digestive system caspa expression increased amount, abnormal chemical treatment by environment: navitoclax Figure 6 with image from Novoa et al., 2019
digestive system cdkn1a expression increased amount, abnormal chemical treatment by environment: O-acetylcarnitinium Figure 5 with image from Novoa et al., 2019
digestive system il1b expression increased amount, abnormal standard conditions Figure 6 with image from Novoa et al., 2019
digestive system tnfa expression increased amount, abnormal standard conditions Figure 6 with image from Novoa et al., 2019
digestive system nfe2l2a expression increased amount, abnormal standard conditions Graph Figure 4 from Novoa et al., 2019
digestive system caspa expression increased amount, abnormal standard conditions Figure 6 with image from Novoa et al., 2019
digestive system cdkn1a expression increased amount, abnormal standard conditions Figure 5 with image from Novoa et al., 2019
digestive system mxe expression increased amount, abnormal chemical treatment by environment: O-acetylcarnitinium Figure 6 with image from Novoa et al., 2019
digestive system mxe expression increased amount, abnormal chemical treatment by environment: navitoclax Figure 6 with image from Novoa et al., 2019
digestive system mdm2 expression increased amount, abnormal standard conditions Figure 5 with image from Novoa et al., 2019
fin morphology, abnormal bacterial treatment by injection: Mycobacterium leprae Fig. 2 with image from Madigan et al., 2017
granuloma formation increased occurrence, abnormal bacterial treatment by injection: Mycobacterium leprae Fig. 2 with image from Madigan et al., 2017
immunoglobulin heavy chain V-D-J recombination disrupted, abnormal standard conditions Fig. 3 from Wienholds et al., 2002
inflammatory response to antigenic stimulus decreased efficacy, abnormal standard conditions text only from Tokunaga et al., 2017
integument beta-galactosidase activity increased occurrence, abnormal standard conditions Figure 5 with image from Novoa et al., 2019
integument beta-galactosidase activity increased occurrence, ameliorated chemical treatment by environment: O-acetylcarnitinium Figure 5 with image from Novoa et al., 2019
integument beta-galactosidase activity increased occurrence, ameliorated chemical treatment by environment: navitoclax Figure 5 with image from Novoa et al., 2019
integument leukocyte ab1-il1b labeling increased distribution, abnormal standard conditions Figure 3 with image from Novoa et al., 2019
integument macrophage increased amount, abnormal standard conditions Figure 3 with image from Novoa et al., 2019
integument neutrophil Ab5-mpx labeling absent, abnormal standard conditions Figure 3 with image from Novoa et al., 2019
intestine il17a/f3 expression amount, ameliorated diet Fig. 5 from Coronado et al., 2019
intestine lck expression amount, ameliorated diet Fig. 5 from Coronado et al., 2019
intestine traj3c1-3 expression amount, ameliorated diet Fig. 5 from Coronado et al., 2019
intestine il17a/f1 expression amount, ameliorated diet Fig. 5 from Coronado et al., 2019
intestine cd4-1 expression amount, ameliorated diet Fig. 5 from Coronado et al., 2019
intestine il22 expression decreased amount, abnormal diet Fig. 5 from Coronado et al., 2019
intestine morphology, normal standard conditions Fig. 4 from Jima et al., 2009
kidney prf1.5 expression decreased amount, abnormal standard conditions Fig. 6 from Varela et al., 2016
kidney prf1.6 expression decreased amount, abnormal standard conditions Fig. 6 from Varela et al., 2016
kidney prf1.2 expression increased amount, abnormal standard conditions Fig. 6 from Varela et al., 2016
kidney prf1.1 expression increased amount, abnormal standard conditions Fig. 6 from Varela et al., 2016
kidney prf1.9 expression increased amount, abnormal standard conditions Fig. 6 from Varela et al., 2016
kidney prf1.3 expression increased amount, abnormal standard conditions Fig. 6 from Varela et al., 2016
kidney morphology, normal standard conditions Fig. 4 from Jima et al., 2009
kidney apoptotic process increased occurrence, abnormal standard conditions Figure 2 with image from Novoa et al., 2019
kidney catalase activity decreased efficacy, abnormal standard conditions Graph Figure 4 from Novoa et al., 2019
kidney cell cycle G1/S phase transition delayed, abnormal standard conditions Figure 2 with image from Novoa et al., 2019
kidney chromosome, telomeric region decreased length, abnormal standard conditions Figure 2 with image from Novoa et al., 2019
kidney granulocyte increased amount, abnormal standard conditions text only from Tokunaga et al., 2017
kidney granulocyte increased amount, abnormal chemical treatment by injection: poly(I:C) text only from Tokunaga et al., 2017
kidney cell Ab13-h2ax labeling increased amount, abnormal standard conditions Figure 2 with image from Novoa et al., 2019
kidney cell Ab13-h2ax labeling increased distribution, abnormal standard conditions Figure 2 with image from Novoa et al., 2019
lateral zone olfactory bulb morphology, normal standard conditions Fig. 5 with image from Feng et al., 2005
liver il17a/f2 expression increased amount, abnormal chemical treatment by injection: poly(I:C) text only from Tokunaga et al., 2017
liver il17a/f3 expression increased amount, abnormal chemical treatment by injection: poly(I:C) text only from Tokunaga et al., 2017
liver il13 expression increased amount, abnormal chemical treatment by injection: poly(I:C) text only from Tokunaga et al., 2017
liver il10 expression increased amount, abnormal chemical treatment by injection: poly(I:C) text only from Tokunaga et al., 2017
liver morphology, normal standard conditions Fig. 4 from Jima et al., 2009
liver 8-hydroxy-2'-deoxyguanosine increased amount, abnormal standard conditions Graph Figure 4 from Novoa et al., 2019
liver catalase activity decreased efficacy, abnormal standard conditions Graph Figure 4 from Novoa et al., 2019
liver cellular lipid catabolic process increased occurrence, abnormal standard conditions Graph Figure 4 from Novoa et al., 2019
liver hepatocyte il6 expression increased amount, abnormal standard conditions Figure 6 with image from Novoa et al., 2019
liver hepatocyte il6 expression increased distribution, abnormal standard conditions Figure 6 with image from Novoa et al., 2019
liver macrophage increased amount, abnormal chemical treatment by injection: poly(I:C) text only from Tokunaga et al., 2017
lymphocyte absent, abnormal bacterial treatment by injection: Mycobacterium leprae Fig. 2 with image from Madigan et al., 2017
mature B cell absent, abnormal standard conditions text only from Tokunaga et al., 2017
muscle leukocyte ab1-il1b labeling increased distribution, abnormal standard conditions Figure 3 with image from Novoa et al., 2019
muscle macrophage increased amount, abnormal standard conditions Figure 3 with image from Novoa et al., 2019
muscle neutrophil Ab5-mpx labeling absent, abnormal standard conditions Figure 3 with image from Novoa et al., 2019
pancreas il13 expression increased amount, abnormal chemical treatment by injection: poly(I:C) text only from Tokunaga et al., 2017
pancreas il17a/f2 expression increased amount, abnormal chemical treatment by injection: poly(I:C) text only from Tokunaga et al., 2017
pancreas il17a/f3 expression increased amount, abnormal chemical treatment by injection: poly(I:C) text only from Tokunaga et al., 2017
pancreas il10 expression increased amount, abnormal chemical treatment by injection: poly(I:C) text only from Tokunaga et al., 2017
pancreas macrophage increased amount, abnormal chemical treatment by injection: poly(I:C) text only from Tokunaga et al., 2017
retina leukocyte ab1-il1b labeling increased distribution, abnormal standard conditions Figure 3 with image from Novoa et al., 2019
retina macrophage increased amount, abnormal standard conditions Figure 3 with image from Novoa et al., 2019
retina neutrophil Ab5-mpx labeling absent, abnormal standard conditions Figure 3 with image from Novoa et al., 2019
sensory neuron axon guidance process quality, normal standard conditions Fig. 5 with image from Feng et al., 2005
spleen tnfa expression decreased amount, abnormal chemical treatment by injection: poly(I:C) text only from Tokunaga et al., 2017
spleen granulocyte increased amount, abnormal chemical treatment by injection: poly(I:C) text only from Tokunaga et al., 2017
spleen macrophage increased amount, abnormal chemical treatment by injection: poly(I:C) text only from Tokunaga et al., 2017
whole organism decreased size, abnormal bacterial treatment by injection: Mycobacterium leprae Fig. 2 with image from Madigan et al., 2017
whole organism fertile, normal standard conditions text only from Wienholds et al., 2002
whole organism nlrp12l expression increased amount, abnormal standard conditions Graph Figure 1 from Novoa et al., 2019
whole organism mxe expression increased amount, abnormal standard conditions Graph Figure 1 from Novoa et al., 2019
whole organism acod1 expression increased amount, abnormal standard conditions Graph Figure 1 from Novoa et al., 2019
whole organism trim35-14 expression increased amount, abnormal standard conditions Graph Figure 1 from Novoa et al., 2019
whole organism mxa expression increased amount, abnormal standard conditions Graph Figure 1 from Novoa et al., 2019
whole organism tnfrsf9a expression increased amount, abnormal standard conditions Graph Figure 1 from Novoa et al., 2019
whole organism shisa10.2 expression increased amount, abnormal standard conditions Graph Figure 1 from Novoa et al., 2019
whole organism caspa expression increased amount, abnormal standard conditions Graph Figure 1 from Novoa et al., 2019
whole organism prf1.2 expression increased amount, abnormal standard conditions Graph Figure 1 from Novoa et al., 2019
whole organism lacks parts or has fewer parts of type blood IgM immunoglobulin complex, abnormal standard conditions text only from Tokunaga et al., 2017
whole organism lacks parts or has fewer parts of type thymus, abnormal standard conditions Fig. 4 with image from Tokunaga et al., 2017
whole organism viability, abnormal standard conditions Figure 2 with image from Novoa et al., 2019
whole organism viability, abnormal bacterial treatment by injection: Mycobacterium leprae Fig. 2 with image from Madigan et al., 2017
whole organism viable, normal standard conditions text only from Wienholds et al., 2002

CITATIONS  (18)